The global prostaglandin market is anticipated to record a moderate CAGR over the forecast period, i.e., 2021-2029. The market is primarily driven by the increasing complications observed among women during labor in the process of childbirth, along with the increasing use of prostaglandins in obstetric practices.
Prostaglandins are hormone-like compounds that are derived enzymatically in the human body from arachidonic acid (a type of fatty acid). The primary function of prostaglandin in humans is to create eicosanoids hormones, induce fever by acting on the thermoregulatory center of the hypothalamus, and initiate labor in pregnancy. During the process of childbirth, prostaglandin helps to contract the muscles of the uterine walls, which helps to push the baby out of the uterus. The suppositories of prostaglandin are inserted into the vagina in the evening which helps the mother go into labor by the next morning. Further, when the human or animal body is bleeding, prostaglandins stimulate the formation of blood clots and contraction of blood vessels. Apart from the use of prostaglandins in the reproductive area, it is widely distributed in the human body to produce different pharmacological effects, such as regulation of blood pressure, treatment of hypertension, and peripheral vascular disease among others. These compounds are also used clinically for induction of labor and to reduce early pregnancies. Primarily, there are four different types of prostaglandin, namely, prostaglandin I2 (PGI2), prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), and prostaglandin F2 alpha (PGF2∞), the comparison of which is given below:
The global prostaglandin market is further thriving on account of the numerous properties associated with the compound, which makes it widely accepted in different health applications, including cardiology, gastroenterology, ophthalmology, gynecology & obstetrics, and others. Also, the role of prostaglandins in the pathophysiology and treatment of various vascular disorders by the utilization of the compound is further expected to boost the market growth in the near future. The market is segmented on the basis of application into cardiology, gastroenterology, ophthalmology, gynecology & obstetrics, and others, out of which, the cardiology segment is projected to account for the leading market share in the year 2021 on the back of an increasing number of geriatric populations across the globe and the growing incidences of cardiovascular diseases worldwide. According to the statistics by the World Health Organization (WHO), the proportion of the global population aged 60 years and above is projected to double from 12% to 22% between 2015 and 2050. Alternatively, the gynecology & obstetrics segment is projected to grow with the highest CAGR during the forecast period on account of the increasing applications of human prostaglandin medications in women during pregnancy. Further, the growing utilization of prostaglandin synthetase inhibitors, such as ibuprofen, indomethacin, ibuprofen and mefenamic acid for the treatment of primary dysmenorrhea, is also anticipated to help drive the growth of the segment during the forecast period. CLICK TO DOWNLOAD SAMPLE REPORT
Migraine is a neurological condition that is frequently characterized by debilitating and intense headaches. Some of the major symptoms caused by migraines include vomiting, sensitivity to light & sound, nausea, and others. One of the major reasons for implicating prostaglandins in pathogenesis is for the cause of migraine headaches. These compounds are able to constrict or relax the cerebral blood vessels, which helps in reducing migraine headaches. Moreover, these compounds have reportedly known to potentiate the effects of bradykinin and other forms of chemically induced pain by sensitizing the peripheral pain receptors. Additionally, prostaglandin also helps in the diagnosis of inflammatory diseases, such as edema, erythema, and tissue damage, and is capable of modulating the release of neurotransmitters from nerve terminals. Prostaglandin inhibitors are also effectively used for shortening the duration of migraine attacks and reduce the side effects such as nausea, vomiting, and abdominal pain.
In other statistics by the WHO, every year 17.9 million people die due to cardiovascular diseases.
Development in the area of neonatal cardiac surgery has increased the importance of rapid diagnosis and stabilization of infants with congenital heart disease. With the increasing applications of prostaglandin in the early stages of detection of cardiovascular diseases, the compound helps the patients to be more clinically stable for surgery. Therapy with prostaglandin can effectively maintain an infant's cardiovascular function until a palliative or corrective procedure can be performed. Additionally, the growing geriatric population with major congenital heart disease is further projected to enhance the market growth over the forecast period.
The primary issues with uneven prostaglandins are the unwanted inflammation in the body. Excessive production of prostaglandin can cause chronic diseases with significant pain. Moreover, menstruation bleeding, arthritis, and some types of cancer, among others are connected to the high amount of prostaglandin formation. Sometimes, the formation of prostaglandin is not enough to heal the injury, which in turn is also anticipated to hamper the market growth over the forecast period.
Our in-depth analysis of the global prostaglandin market includes the following segments:
On the basis of regional analysis, the global prostaglandin market is segmented into five major regions including North America, Europe, Asia Pacific and the Middle East & Africa region. Among these regions, the market in North America is expected to display significant growth owing to the increasing number of patients having congenital heart diseases. According to the statistics by the Centers for Disease Control and Prevention (CDC), about 655,000 Americans die from heart disease each year. Moreover, the presence of a strong healthcare network in the region, along with increasing investments by the pharmaceutical companies for the research and development of advanced hormone-like compounds are some of the additional factors anticipated to drive the market growth in North America.
The global prostaglandin market is further classified on the basis of region as follows:
FREQUENTLY ASKED QUESTIONS
Increasing use of prostaglandins in obstetric practices, along with growing application of prostaglandin in treating different health disorders, are some of the major factors driving the market growth.
The market is anticipated to attain a moderate CAGR over the forecast period, i.e., 2021-2029.
The major companies in the market are Enzo Life Sciences, Inc., Merck KGaA, Alfa Chemistry, AbMole BioScience, R&D Systems, Inc, Chirogate International Inc., Cayman Chemical, Pfizer Inc., and others.
The company profiles are selected based on the revenues generated from segments, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The prostaglandin market is segmented by type, application, and by region.
The cardiology segment, which is a sub-segment of the application segment, is anticipated to hold the dominating share owing to the increasing incidences of cardiovascular diseases around the globe.
Growing concerns for the health issues, such as excessive menstruation bleeding, cancer diseases and other chronic diseases among others are some of the major factors estimated to act as barriers to the growth of the market.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization